Adcomfo
Omalizumab biosimilar developed by Not stated in the MHRA list. Reference product Xolair.
Brands by market: Adcomfo (UK) · Commercial partner or holder: UK licence holder not shown in the list
FDANot listed
EMANot listed
MHRALicenseddate not shown
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
About Adcomfo
Adcomfo is an omalizumab licensed in the United Kingdom in 75 mg and 150 mg syringes, the second omalizumab biosimilar there after Omlyclo. The MHRA list does not show its holder or developer.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
MHRA
United Kingdom · Adcomfo
Medicines and Healthcare products Regulatory AgencyApprovedBrand
Adcomfo
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
75 mg and 150 mg syringes
Source
S023 (MHRA Products) · checked Sep 2026
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
Sources
S023MHRA Products, substance lists of licensed medicines (products.mhra.gov.uk) Primary (regulator)
Planning omalizumab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.